Top 10 Oncology Products by Global Sales in 2024OncologyExplore the top 10 global oncology drugs of 2024 by sales. Discover leading therapies like Keytruda and Darzalex, modality trends, solid vs. blood tumor market insights, and the growing role of cell and gene therapies.
2024 Global Top 10 Pharmaceutical CompaniesMarket TrendThe 2024 global ranking of the top 10 pharmaceutical companies showcases the continued strength of industry leaders like Johnson & Johnson, Roche, and Merck. Pfizer, AstraZeneca, and Eli Lilly also maintain strong positions with impressive growth and strategic investments.
Top 10 Pharmaceutical Giants' R&D Investments in 2024Market TrendIn 2024, pharmaceutical giants face a quiet battle over innovation and efficiency. From Merck’s 41% R&D drop to AbbVie’s bold growth, their strategies and investments reveal shifting power in the industry. A glimpse into the future of drug development.
Top 16 Best-Selling New Drugs Worldwide in 2024Market TrendDiscover the top 16 best-selling new drugs of 2024, featuring innovative FIC and BIC molecules, breakthrough therapies across various fields, and products that stood out due to unique development strategies.
Top 10 Global Pharmaceutical Giants in Oncology Business for 2024OncologyDiscover the top 10 pharmaceutical giants leading the oncology industry in 2024. From Merck's dominance with Keytruda to AstraZeneca's rise, these companies are making strides in cancer treatment, innovation, and growth.
Top 10 Global Pharmaceutical Giants in Autoimmune Business in 2024AutoimmuneThe autoimmune sector saw explosive growth in 2024, with mergers and acquisitions skyrocketing by 150%. Giants like AbbVie, J&J, and Eli Lilly are reshaping the landscape. Explore the Top 10 revenue rankings in the autoimmune business and future trends.
Pharmaceutical Giants Ranking 2024Market TrendExplore the top pharmaceutical giants of 2024, including Merck, Johnson & Johnson, and more. Learn about their revenue, profits, R&D investments, and market value in this detailed ranking report.
Roche 2024 Financial ReportFinancial statementsRoche's 2024 financial report reveals a 7% revenue growth, driven by strong sales of ophthalmology drug Vabysmo and a solid performance in China. Key therapeutic areas like oncology and neurology continue to show growth.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
